Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Moderna to Present Phase 3 Melanoma Data at ESMO 2026

Guavy AI Editorial Team
Instruments
MRK
Share

Moderna, Inc. (MRNA) has announced that it will present phase 3 data for its intismeran autogene treatment in adjuvant melanoma at the upcoming ESMO 2026 Presidential Symposium.

The company stated that this late-breaking data will be presented during a high-profile session, indicating potential significance of the findings. A related investor webcast is scheduled to take place on October 24th, which may provide additional insights from management that could impact stock performance.

The partnership between Moderna and Merck (MSD ex-U.S.) implies shared costs and potential upsides for both companies, adding credibility to this development in the oncology pipeline.

More on Stocks

Stocks just now

Apple Unveils Foldable iPhone Duo with Premium Price Tag

Stocks just now

UnitedHealth Tokenized Stock Enters Growing Market for Blockchain-Based Assets

Stocks 1m ago

UnitedHealth Group: Profit Over People in America's Healthcare System

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy